Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

77.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics
 
Via Benzinga
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Via ACCESS Newswire
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million 
Via The Motley Fool
Topics Energy
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million 
Via The Motley Fool
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million 
Via The Motley Fool
Topics Regulatory Compliance
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
Via Stocktwits
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
2 Top Dividend Kings Every Income Investor Should Own
These companies pay durable and steadily rising dividends. 
Via The Motley Fool
Topics Bonds
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets. 
Via MarketBeat
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. 
Via Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst. 
Via Benzinga
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit. 
Via Benzinga
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears
U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and... 
Via Chartmill
Topics Artificial Intelligence Government World Trade
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
The company could soon be swallowed by a very large peer -- which also happens to be a business partner. 
Via The Motley Fool
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio. 
Via Benzinga
Which stocks are experiencing notable movement on Friday?
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
5 Analysts Assess Protagonist Therapeutics: What You Need To Know
 
Via Benzinga
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Via ACCESS Newswire
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews
 
Via Benzinga
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis. 
Via Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Via ACCESS Newswire
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Via ACCESS Newswire
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
 
Via Benzinga
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Via ACCESS Newswire
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Via ACCESS Newswire
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.